Text Size

Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment (EXCITING)

This study has been terminated.
(Termination of study due to low enrollment)
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00881205
First received: April 14, 2009
Last updated: March 8, 2012
Last verified: March 2012
History of Changes

April 14, 2009
March 8, 2012
April 2009
January 2011   (final data collection date for primary outcome measure)
Change From Baseline to Week 16 in Total Recall on the Selective Reminding Test (SRT) in the Intent to Treat (ITT) Population [ Time Frame: After 16 weeks of treatment ] [ Designated as safety issue: No ]
The Selective Reminding Test(SRT) is a test to assess verbal learning and memory. During the administration of the SRT only the examiner and the patient should be in the testing room. A list of twelve words is read aloud by the examiner at a rate of one word per two seconds. The patient is asked to recall all twelve words. Only the words that are missed on the preceding trial are given in the consecutive trial. The total score represents a sum score of 6 trials, therefore the range is from 0-72. The lower the value the worse the outcome.
Demonstrate that rivastigmine patch (target patch size 10 cm²) has superior efficacy compared to placebo on a change from baseline of the total recall score of the selective reminding test of the Brief Repeatable Battery (BRB) of Neuropsychological Test [ Time Frame: After 16 weeks of treatment ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00881205 on ClinicalTrials.gov Archive Site
Not Provided
  • Evaluate the effect of rivastigmine patch vs. placebo on cognition: subtests of the BRB as well as the composite index of the BRB-N: Symbol digit modalities test, Paced auditory serial addition test, Spatia recall test, Word list gene [ Time Frame: After 16 weeks of treatment ] [ Designated as safety issue: No ]
  • To evaluate the effect of rivastigmine patch vs. placebo on fatigue: Modified Fatigue Impact Scale (mFIS) [ Time Frame: after 16 weeks of treatment ] [ Designated as safety issue: No ]
  • To evaluate the effect of rivastigmine patch vs. placebo on depression: Montgomery-Åsberg Depression Scale (MADRS) [ Time Frame: after 16 weeks of treatment ] [ Designated as safety issue: No ]
  • To evaluate the effect of rivastigmine patch vs. placebo on Quality of Life (QoL): patient reported impact of multiple sclerosis (PRIMuS) [ Time Frame: after 16 weeks of treatment ] [ Designated as safety issue: No ]
  • To evaluate the effect of rivastigmine patch vs. placebo on global impression: clinical global impression scale (CGI) [ Time Frame: after 16 weeks of treatment ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
A 16-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm²) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-year Open-label Treatment Phase

This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients. Primary objective was the assessment of cognition by the Selective Reminding Test (SRT) -a subtest of the brief repeatable battery (BRB) - after titration of 4 weeks and maintenance of 12 weeks. This double-blind period was followed by a 52-week open-label treatment phase to assess long-term safety of rivastigmine patch in these patients.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Multiple Sclerosis
  • Cognitive Impairment
  • Drug: Rivastigmine transdermal patch
    Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
  • Drug: Placebo
    Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
  • Experimental: Rivastigmine
    Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
    Intervention: Drug: Rivastigmine transdermal patch
  • Placebo Comparator: Placebo
    Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
86
January 2011
January 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Written informed consent to participate in the trial
  2. Males and females between 18 and 55 years of age;
  3. Definite diagnosis of multiple sclerosis as defined by 2005 revised McDonald criteria
  4. MS-subtype: Clinical isolated syndrome (CIS), Relapsing Remitting Multiple Sclerosis (RRMS), Secondary progressive Multiple Sclerosis (SPMS);
  5. Cognitive Impairment
  6. Sufficient education to read, write and communicate comprehensibly

Exclusion Criteria:

  1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
  2. Women who are pregnant or breast feeding or who are menstruating and capable of becoming pregnant and not practicing a medically approved method of contraception
  3. With a physical or sensory disability that can subjectively prevent the patient from completing all study requirements
  4. Patients suffering any other type of concomitant psychiatric and/or neurological disorder other than MS which is known to affect cognition (e.g. severe depressive symptoms, cerebrovascular diseases, epilepsy).
  5. Patients suffering an acute relapse of MS in the previous 30 days (treated or not with intravenous or oral glucocorticoid regimens) prior to baseline.
  6. With a history or current problem of drug-addiction and/or alcohol abuse.
  7. Known or 'new' diagnosis of diabetes mellitus (if screening blood glucose is suspicious for diabetes [≥126 mg/dL or ≥7 mmol/L if fasting and ≥200 mg/dL or 11.1 mmol/L if random testing] a patient should be further evaluated for diabetes mellitus)
  8. With a history of severe or moderate-severe cranioencephalic trauma.
  9. History or presence of any intolerance or contraindication for the application of rivastigmine (or for drugs with similar chemical structures) as listed in the current Investigator's Brochure and/or SPC, i.e. severe liver insufficiency, pancreatitis, gastric ulcer, convulsions.
  10. With a history in the past year or a current diagnosis of cerebrovascular disease (for instance, stroke, transient ischemic events, aneurysms).
  11. Severe depressive symptoms indicated by a score of more than ≥ 14 on the MADRS at screening
  12. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin

Other protocol-defined inclusion/exclusion criteria may apply
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00881205
CENA713DDE18
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP